The Latin America, Middle East and Africa Hospital-Acquired Infection Diagnostics Market is expected to witness market growth of 11.5% CAGR during the forecast period (2022-2028).
To cure patients and aid in recovery, modern healthcare uses a variety of invasive technologies and procedures. Infections have been linked to medical devices like catheters and ventilators. Central line-associated bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections are examples of healthcare-associated infections (HAIs). Surgical site infections are infections that occur at the surgical site. This is because the illnesses pose a significant risk to patient safety, the CDC and other healthcare institutions strives to check and prevent them.
When a catheter-associated urinary tract infection is suspected, the old catheter must be withdrawn and a urine sample taken from the newly inserted catheter, ideally before antibiotics are started. The steps have been demonstrated to increase microbiological specimen output. All catheters comprising central lines and urine catheters should be withdrawn if it is no longer needed as part of the standby precautions. Antibiotics for seven days are usually indicated for catheter-associated UTIs. The antibiotic prescription could be stretched to 10-14 days if there is a slow response or bacteremia. Antimicrobial catheters, antibiotic prophylaxis, and antimicrobial catheters, in some settings, can help prevent CAUTI.
The UAE has a solid healthcare infrastructure as one of the most economically developed and diverse marketplaces in the Middle East region. The UAE government has prioritized the development of world-class healthcare infrastructure, and as a result, the sector has grown and expanded greatly in recent years. In addition, the UAE healthcare sector has grown to satisfy the country's changing demands as well as its desire to become a regional medical tourism destination. As the prevalence of lifestyle diseases rises, the populations, whose incomes are relatively high, continue to seek higher-quality healthcare. The government has committed to building healthcare infrastructure to accommodate the need.
They are liberalizing rules in order to attract international investment and better the healthcare standard and industry. The concerned authority wants to enhance health-care funding so that more data monitoring tools can be used for proactive COVID contact tracing and virtual medical service providers can be licensed. The government also intends to strengthen national capacities to combat future pandemics, including vaccine and pharmaceutical development, digital immunization IDs, and a new supply chain strategy. The Ministry of Health wants to grow the industry by concentrating on health information technology, such as telemedicine and digital medicine.
The Brazil market dominated the LAMEA Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $115 million by 2028. The Argentina market is experiencing a CAGR of 12.1% during (2022 - 2028). Additionally, The UAE market is expected to exhibit a CAGR of 11.2% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
To cure patients and aid in recovery, modern healthcare uses a variety of invasive technologies and procedures. Infections have been linked to medical devices like catheters and ventilators. Central line-associated bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections are examples of healthcare-associated infections (HAIs). Surgical site infections are infections that occur at the surgical site. This is because the illnesses pose a significant risk to patient safety, the CDC and other healthcare institutions strives to check and prevent them.
When a catheter-associated urinary tract infection is suspected, the old catheter must be withdrawn and a urine sample taken from the newly inserted catheter, ideally before antibiotics are started. The steps have been demonstrated to increase microbiological specimen output. All catheters comprising central lines and urine catheters should be withdrawn if it is no longer needed as part of the standby precautions. Antibiotics for seven days are usually indicated for catheter-associated UTIs. The antibiotic prescription could be stretched to 10-14 days if there is a slow response or bacteremia. Antimicrobial catheters, antibiotic prophylaxis, and antimicrobial catheters, in some settings, can help prevent CAUTI.
The UAE has a solid healthcare infrastructure as one of the most economically developed and diverse marketplaces in the Middle East region. The UAE government has prioritized the development of world-class healthcare infrastructure, and as a result, the sector has grown and expanded greatly in recent years. In addition, the UAE healthcare sector has grown to satisfy the country's changing demands as well as its desire to become a regional medical tourism destination. As the prevalence of lifestyle diseases rises, the populations, whose incomes are relatively high, continue to seek higher-quality healthcare. The government has committed to building healthcare infrastructure to accommodate the need.
They are liberalizing rules in order to attract international investment and better the healthcare standard and industry. The concerned authority wants to enhance health-care funding so that more data monitoring tools can be used for proactive COVID contact tracing and virtual medical service providers can be licensed. The government also intends to strengthen national capacities to combat future pandemics, including vaccine and pharmaceutical development, digital immunization IDs, and a new supply chain strategy. The Ministry of Health wants to grow the industry by concentrating on health information technology, such as telemedicine and digital medicine.
The Brazil market dominated the LAMEA Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $115 million by 2028. The Argentina market is experiencing a CAGR of 12.1% during (2022 - 2028). Additionally, The UAE market is expected to exhibit a CAGR of 11.2% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Reagents & Consumables
- Instrument
By Infection Type
- Urinary Tract Infections (UTI)
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Others
By Application
- Drug-Resistance Testing
- Disease Testing
By Test Type
- Molecular Diagnostics
- Immunoassay
- Urinalysis
By End User
- Hospital
- Standalone Laboratories
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Hospital-Acquired Infection Diagnostics Market by Product
Chapter 5. LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type
Chapter 6. LAMEA Hospital-Acquired Infection Diagnostics Market by Application
Chapter 7. LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type
Chapter 8. LAMEA Hospital-Acquired Infection Diagnostics Market by End User
Chapter 9. LAMEA Hospital-Acquired Infection Diagnostics Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Methodology
LOADING...
